养胃配方颗粒组方对慢性萎缩性胃炎患者血清炎症指标及中医症状积分影响
|
摘要
目的:探讨养胃配方颗粒组方对慢性萎缩性胃炎患者血清炎症指标及中医症状积分的影响。方法:选取2014年5月—2015年6月在我院住院部及门诊就诊被诊断为慢性萎缩性胃炎的患者90例,采用随机数字表法分为对照组和实验组,实验组应用院内协定处方养胃配方颗粒组方,对照组给予维酶素片,两组治疗3个疗程。结果:治疗前,实验组及对照组IL-32、CRP水平比较无明显差异,治疗后,实验组IL-32、CRP分别为(40.34±10.65)pg/m L、(8.35±4.31)mg/L,较对照组(52.25±9.21)pg/m L(21.56±3.27)mg/L水平低,差异有统计学意义,、P<0.05;治疗前,两组证候积分无明显差异,治疗后,两组中医证候均有所下降,其中身倦乏力、便溏腹泻两组之间无明显差异,实验组胃脘隐痛、反酸烧心、食后脘闷、纳呆少食、恶心呕吐及中医证候总积分均较对照组低,差异有统计学意义,P<0.05;实验组总有效率为84.44%,对照组总有效率为73.33%,差异有统计学意义,P<0.05。结论:养胃配方颗粒组方可以改善慢性萎缩性胃炎患者中医证候,降低血清IL-32及CRP水平。
Objective:To investigation the effect of Yangwei Granule prescription on chronic atrophic gastritis serum inflammation indexes and TCM symptom score. Methods:90 cases of patients diagnosed as chronic atrophy gastritis were selected in May 2014 to June 2015 in our hospital hospitalization department and outpatient,were randomly divided into experimental group and control group,the experimental group used in hospital agreement prescription Yangwei Granule prescription,the control group were treated with Weimeisu Tablets. Results:Before treatment,the experimental group and the control group,the IL-32 level of CRP had no significant difference,after treatment,the experimental group IL-32 and CRP were(40.34±10.65)pg/m L,(8.35±4.31)mg/L,compared with the control group(52.25±9.21)pg/m L,(21.56±3.27)mg/L level is low,the difference was significant meaning,P<0.05;before treatment,no significant difference between the two groups,symptom scores after treatment,two groups of TCM syndromes were decreased,the body tired fatigue,loose stools,diarrhea no significant difference between the two groups,the experimental group of epigastric pain,heartburn,abdominal nausea after eating,loss of appetite,nausea and vomiting and the TCM syndrome total score was lower than the control group,the difference was statistically significant,P<0.05;the total efficiency of the experimental group was 84.44%,control group total effective rate was 73.33%,the difference was statistically significant,P<0.05. Conclusion:Yangwei Granule prescription can improve patients with chronic atrophic gastritis of TCM syndrome,reduce serum IL-32 and CRP levels.
Objective:To investigation the effect of Yangwei Granule prescription on chronic atrophic gastritis serum inflammation indexes and TCM symptom score. Methods:90 cases of patients diagnosed as chronic atrophy gastritis were selected in May 2014 to June 2015 in our hospital hospitalization department and outpatient,were randomly divided into experimental group and control group,the experimental group used in hospital agreement prescription Yangwei Granule prescription,the control group were treated with Weimeisu Tablets. Results:Before treatment,the experimental group and the control group,the IL-32 level of CRP had no significant difference,after treatment,the experimental group IL-32 and CRP were(40.34±10.65)pg/m L,(8.35±4.31)mg/L,compared with the control group(52.25±9.21)pg/m L,(21.56±3.27)mg/L level is low,the difference was significant meaning,P<0.05;before treatment,no significant difference between the two groups,symptom scores after treatment,two groups of TCM syndromes were decreased,the body tired fatigue,loose stools,diarrhea no significant difference between the two groups,the experimental group of epigastric pain,heartburn,abdominal nausea after eating,loss of appetite,nausea and vomiting and the TCM syndrome total score was lower than the control group,the difference was statistically significant,P<0.05;the total efficiency of the experimental group was 84.44%,control group total effective rate was 73.33%,the difference was statistically significant,P<0.05. Conclusion:Yangwei Granule prescription can improve patients with chronic atrophic gastritis of TCM syndrome,reduce serum IL-32 and CRP levels.
引文
[1]陈佳,李守英,徐红,等.慢性萎缩性胃炎的研究进展[J].中国老年学杂志,2013,33(14):3540-3542.
[2]李树标,庞家善,徐奎,等.慢性萎缩性胃炎的中医药研究进展[J].中国民族民间医药,2010,19(5):83-85.
[3]付美艳,彭连红,李迎,等.中西医结合治疗慢性萎缩性胃炎疗效观察与分析[J].医学信息,2015(32):95-95.
[4]杨国强.慢性萎缩性胃炎的临床治疗[J].中国社区医师,2016,32(8):101-102.
[5]杜进璇,曾斌芳,王宁,等.中西医结合(养阴活胃合剂与标准根除Hp治疗)治疗慢性萎缩性胃炎129例的临床研究[J].新疆中医药,2015,33(3):26-29.
[6]祖宝宏.中西医结合治疗慢性萎缩性胃炎35例[J].中国中西医结合消化杂志,2011,19(2):131.
[7]牛兴东,牛克梅,徐敏和,等.慢性萎缩性胃炎西医检查与中医辨证分型的相关性研究[C]//中华中医药学会脾胃病分会第十九次全国脾胃病学术交流会论文集.石家庄:中华中医药学会脾胃病分会,2007:84-87.
[8]李涛.慢性萎缩性胃炎中医治疗疗效观察[J].中医临床研究,2014(15):78-79.
[9]张英,张金超,陈瑶,等.广藿香生药、化学及药理学的研究进展[J].中草药,2006,37(5):786-790.
[10]王红勋.枳实与枳壳的现代药理与临床应用研究[J].中国卫生标准管理,2014(16):39-40.
[11]刘东林,王小莹,杨冰,等.槟榔药理毒理研究进展[J].中国中药杂志,2013,38(14):2273-2275.
[12]李洪京.陈皮的药理分析及临床应用研究[J].医学信息,2015,28(6):100-101.
[13]郭强.厚朴与厚朴花现代药理与临床新用分析[J].中国卫生标准管理,2014(16):31-32.
[14]李佳,刘继永.中药威灵仙的化学成分及药理作用研究进展[J].特产研究,2011,33(1):67-71,75.
[15]樊永磊,李素荷,钟国新,等.穴位埋线对慢性萎缩性胃炎大鼠血清CRP、IL-6、TNF-α的影响[J].吉林中医药,2013,33(8):824-826.
[16]金菲.慢性萎缩性胃炎患者C反应蛋白测定的临床意义[J].医药前沿,2013(19):182.
[17]李明.慢性胃炎和胃癌患者血清CRP、IL-32水平及其意义[D].青海:青海大学,2014.
[18]孙瑜.感染幽门螺杆菌的慢性萎缩性胃炎患者血清hs-CRP水平及其与Cag-A的关系[J].中国误诊学杂志,2009,9(30):7311-7312.
[19]颜勤,王敏.健脾养胃汤治疗慢性萎缩性胃炎40例[J].陕西中医,2003,24(1):3-4.
[2]李树标,庞家善,徐奎,等.慢性萎缩性胃炎的中医药研究进展[J].中国民族民间医药,2010,19(5):83-85.
[3]付美艳,彭连红,李迎,等.中西医结合治疗慢性萎缩性胃炎疗效观察与分析[J].医学信息,2015(32):95-95.
[4]杨国强.慢性萎缩性胃炎的临床治疗[J].中国社区医师,2016,32(8):101-102.
[5]杜进璇,曾斌芳,王宁,等.中西医结合(养阴活胃合剂与标准根除Hp治疗)治疗慢性萎缩性胃炎129例的临床研究[J].新疆中医药,2015,33(3):26-29.
[6]祖宝宏.中西医结合治疗慢性萎缩性胃炎35例[J].中国中西医结合消化杂志,2011,19(2):131.
[7]牛兴东,牛克梅,徐敏和,等.慢性萎缩性胃炎西医检查与中医辨证分型的相关性研究[C]//中华中医药学会脾胃病分会第十九次全国脾胃病学术交流会论文集.石家庄:中华中医药学会脾胃病分会,2007:84-87.
[8]李涛.慢性萎缩性胃炎中医治疗疗效观察[J].中医临床研究,2014(15):78-79.
[9]张英,张金超,陈瑶,等.广藿香生药、化学及药理学的研究进展[J].中草药,2006,37(5):786-790.
[10]王红勋.枳实与枳壳的现代药理与临床应用研究[J].中国卫生标准管理,2014(16):39-40.
[11]刘东林,王小莹,杨冰,等.槟榔药理毒理研究进展[J].中国中药杂志,2013,38(14):2273-2275.
[12]李洪京.陈皮的药理分析及临床应用研究[J].医学信息,2015,28(6):100-101.
[13]郭强.厚朴与厚朴花现代药理与临床新用分析[J].中国卫生标准管理,2014(16):31-32.
[14]李佳,刘继永.中药威灵仙的化学成分及药理作用研究进展[J].特产研究,2011,33(1):67-71,75.
[15]樊永磊,李素荷,钟国新,等.穴位埋线对慢性萎缩性胃炎大鼠血清CRP、IL-6、TNF-α的影响[J].吉林中医药,2013,33(8):824-826.
[16]金菲.慢性萎缩性胃炎患者C反应蛋白测定的临床意义[J].医药前沿,2013(19):182.
[17]李明.慢性胃炎和胃癌患者血清CRP、IL-32水平及其意义[D].青海:青海大学,2014.
[18]孙瑜.感染幽门螺杆菌的慢性萎缩性胃炎患者血清hs-CRP水平及其与Cag-A的关系[J].中国误诊学杂志,2009,9(30):7311-7312.
[19]颜勤,王敏.健脾养胃汤治疗慢性萎缩性胃炎40例[J].陕西中医,2003,24(1):3-4.